GSK Expects Higher Profits Amid Strong Demand for Vaccines
Drugmaker also warns of slowdown in the months ahead
Shingles shot garnered record revenue in second quarter
Bloomberg News
Updated on
GSK Plc raised its forecasts for the year, saying demand for vaccines and prescription medicines in recent months will make up for a possible slowdown in the second half.
Operating profit excluding some costs will likely rise as much as 15% and sales growth could reach 8%, the UK drugmaker said in a statement Wednesday.
